Cerus (NASDAQ:CERS) Announces Quarterly Earnings Results, Hits Expectations

Cerus (NASDAQ:CERS) released its earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01), Zacks reports. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%.

Cerus Stock Performance

NASDAQ CERS traded down $0.07 during trading on Thursday, reaching $1.74. 1,190,299 shares of the company’s stock were exchanged, compared to its average volume of 1,469,572. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The business has a 50 day moving average price of $1.74 and a 200-day moving average price of $1.84. The stock has a market capitalization of $323.14 million, a P/E ratio of -15.82 and a beta of 1.29. Cerus has a fifty-two week low of $1.38 and a fifty-two week high of $2.59.

Insider Activity

In related news, Director Eric Bjerkholt sold 20,000 shares of Cerus stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the completion of the sale, the director now directly owns 162,133 shares of the company’s stock, valued at approximately $288,596.74. This trade represents a 10.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 3.40% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.